



## FOR IMMEDIATE RELEASE

Contact: Lisa Romero  
Communications & Development Manager  
520-547-3440  
lromero@c-path.org  
[www.c-path.org](http://www.c-path.org)

### CRITICAL PATH INSTITUTE CONTINUES GROWTH

#### Alfred M. Cohen, MD, FACS, FASCRS, Joins as Director, Cancer Biosignature Programs



**Tucson, Arizona, December 9, 2010** – Alfred M. Cohen, MD, FACS, FASCRS, has joined Critical Path Institute (C-Path) as Director of its Cancer Biosignature Programs. Dr. Cohen also serves as Surgical Director of the Arizona Cancer Center and Professor of Surgery in the Section of Surgical Oncology in the Department of Surgery at The University of Arizona. He received his medical degree from the Johns Hopkins University School of Medicine in Baltimore, and completed his general surgery residency at Massachusetts General Hospital in Boston. He obtained surgical oncology and laboratory research training at the National Cancer Institute in Bethesda. Prior to joining The University of Arizona faculty in 2009, Dr. Cohen held the position of Director and Chief Executive Officer of the Lucille P. Markey Cancer Center at the University of Kentucky.

Dr. Cohen was Chief of Colorectal Surgery at Memorial Sloan-Kettering Cancer Center in New York for 15 years, and Director of the Colorectal Cancer Disease Management Team. Prior to that, he was Co-Director of Surgical Oncology at the Massachusetts General Hospital in Boston. He has published 300 articles, reviews, and book chapters. He has been the Principal Investigator of many clinical trials in the treatment of colorectal cancer, and was the Chair of the Colorectal Cancer program for the American College of Surgeons Oncology Group. He is a past President of the Society of Surgical Oncology, the New York Clinical Society, and Chair of the Commission on Cancer at the American College of Surgeons.

“We are extremely fortunate that Dr. Cohen now brings his extensive experience to lead C-Path’s Cancer Biosignature Programs,” said Dr. Ray Woosley, MD, PhD, President and CEO of C-Path. “Biosignatures (multiple, combined tests and characteristics of patients) hold the key to understanding diseases and how best to facilitate their effective diagnosis and treatment.”

In Dr. Cohen’s new role at C-Path, he is responsible for developing and leading the cancer programs for C-Path’s Arizona Biosignatures Laboratory (ABL). Dr. Cohen noted, “This is a tremendous opportunity to work with the U.S. Food and Drug Administration (FDA) and Ventana Medical Systems, C-Path’s industry partner in this work that is sponsored by Science Foundation Arizona. Our goal in ABL is to establish reliable methods for identifying the characteristics of tumors that make it possible to reliably test targeted therapies as potential new cures for cancer.”

---

**About Critical Path Institute (C-Path):** An independent, non-profit organization established in 2005, C-Path is committed to transformational improvement of the drug development process. An international leader in forming collaborations around this mission, C-Path has brought recognition to Arizona through innovative, global programs and partnerships which currently include over 750 scientists from government regulatory agencies, academia, patient advocacy organizations, and thirty major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona, with offices in Phoenix, Arizona, and Rockville, Maryland. For more information, visit [www.c-path.org](http://www.c-path.org).

###